Clinical experience with ceraxon used in ischemic stroke

• Published in: Nevrologii͡a︡, neĭropsikhiatrii͡a︡, psikhosomatika Vol. 2; no. 3; pp. 67 - 70
• Main Authors: V. A. Parfenov, T. G. Fateyeva, O. V. Kosivtsova
• Format: Journal Article
• Language: Russian
• Published: IMA-PRESS LLC 14.09.2010
• Subjects: citicoline (ceraxon); treatment for ischemic stroke
• ISSN: 2074-2711; 2310-1342
• DOI: 10.14412/2074-2711-2010-104

Citicoline (Ceraxon) is a neuroprotective agent used in acute ischemic stroke (IS) and chronic cerebrovascular diseases. The efficiency and safety of Ceraxon intravenously in a dose of2000 mg/day for 10 days, then orally for 35 days with evaluation of its effect on cognitive functions were studied in 24 patients (13 men, 11 women; mean age 68.2+9.3 years) with IS. During treatment, none of the patients died or developed recurrent stroke, myocardial infarction, or other vascular events. A gradual regression of neurological disorders and a lower degree of disability were observed in most patients (18/24). Ceraxon was found to have a positive effect on cognitive function and their improvement on day 45 after disease onset. The findings agree with the results of the multicenter studies showing the efficacy and safety of citicoline in IS.